by Kyle Becker, Becker News:
In the United States, the media barely mention Covid prior infections or the existence of natural immunity.
But a CDC-sponsored database in partnership with Yale, Harvard, and Stanford universities shows that the overwhelming majority of Americans have natural immunity from prior infections, Becker News can exclusively report.
The covidestim database is supported by a cooperative agreement with the CDC and the Council of State and Territorial Epidemiologists.
TRUTH LIVES on at https://sgtreport.tv/
A Becker News analysis drawing on the state-by-state breakdown of prior infections data can be seen in this original graphic below:
The great majority of U.S. states had prior infections ranging between 70% and 94%. Only Hawaii had prior infections data that fell below 50%. The prior infections average for all U.S. states was an incredible 78%.
The CDC released a study last week called “COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021.” The findings were reported by Agence France-Presse.
“During America’s last surge of the coronavirus driven by the Delta variant, people who were unvaccinated but survived Covid were better protected than those who were vaccinated and not previously infected,” AFP noted about the new study.
“The finding is the latest to weigh in on a debate on the relative strengths of natural versus vaccine-acquired immunity against SARS-CoV-2, but comes this time with the imprimatur of the US Centers for Disease Control and Prevention (CDC),” AFP added.
The U.K.’s Health Security Agency (UKHSA), issued a report that echoes much of the CDC’s findings on natural immunity. It showed that those with prior infections to Covid were much less likely to test positive for Covid infections than those in the vaccinated groups.
Those with prior infections even in the pre-Alpha period were tested to have natural immunity roughly equivalent to those with vaccinated immunity acquired from three shots.
The UKHSA report also showed that nearly the entire population of Great Britain has some form of antibodies to Covid-19.
The CDC itself claims there have been 146.6 million prior infections in the United States as of September 2020. Based on its calculation and the current reported 72.9 million “cases,” this would put prior infections and natural immunity at an estimated 250 million to 280 million people (the CDC counts reinfections, particularly of unvaccinated Americans).
Data recently gathered by Imperial College London’s REACT program showed the great majority of Britons reported having overcome a prior Covid infection.
“Of those who reported whether they had a history of COVID-19, almost two-thirds (64.6%) of infections were in people who reported confirmed prior COVID-19,” Imperial College London noted. “However these results are based on self-reported data and therefore it’s uncertain what proportion of these are reinfections or recent infections picked up due to the sensitivity of PCR testing.”
The Africa Health Research Institute in December published a preliminary paper that showed people with Omicron prior infection developed natural immunity to Delta and related variants. The lead author in the pre-print study submitted for publication, Alex Sigal, spearheaded a team of over thirty researchers revealed the promising results.
“The increase neutralizing immunity against Omicron was expected – that is the virus these individuals were infected with,” Sigal noted. “However, we also saw that the same people – especially those who were vaccinated – developed enhanced immunity to the Delta variant. If, as it currently looks like from the South African experience, Omicron is less pathogenic, then this will help push Delta out, as it should decrease the likelihood that someone infected with Omicron will get re-infected with Delta.”
A study on natural immunity was published in the European Journal of Immunology in late December. The research showed that not only is natural immunity effective, it is superior to vaccinated immunity because it is longer-lasting.
The study’s results show the overwhelming majority of subjects received natural immunity from prior infection, regardless of whether the case was ‘severe’ or ‘mild.’ The researchers also sought to assess if natural immunity to certain variants of concern can be expected to protect against future variants.
“Previous infection with SARS-CoV-2 has shown to induce effective immunity and protection against reinfections in most individuals,” the study says.
“Most subjects develop antibodies to SARS-CoV-2 following infection,” the study added. “In order to estimate the duration of immunity induced by SARS-CoV-2 it is important to understand for how long antibodies persist after infection in humans... We found that NAb [natural antibodies] against the WT virus [B-lineage variants] persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection.”
A study in nature immunology shows that children have an even more robust natural immunity response than adults.
“SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear,” the study’s authors state in the abstract. “Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults.”
“Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses,” the study states. “Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months.”
“Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein,” the study notes. “These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens.”